Table 2.
Risk of outcomes comparing rosuvastatin use versus atorvastatin use, overall and across eGFR levels
| Outcome | Unweighted No. of Events/N | IPTW-IR (95% CI), per 1000 PYs | IPTW-IRD (95% CI), per 1000 PYs | P for Heterogeneitya | IPTW-HR (95% CI) | P for Heterogeneitya | ||
|---|---|---|---|---|---|---|---|---|
| Rosuvastatin | Atorvastatin | Rosuvastatin | Atorvastatin | |||||
| Hematuria | ||||||||
| Overall | 5178/152,101 | 22,604/795,799 | 9.2 (8.9 to 9.5) | 8.6 (8.4 to 8.7) | 0.63 (0.31 to 0.95) | 1.08 (1.04 to 1.11) | ||
| eGFR (ml/min per 1.73 m2) | ||||||||
| ≥60 | 4138/130,506 | 18,215/687,461 | 8.4 (8.1 to 8.7) | 7.9 (7.8 to 8.0) | 0.53 (0.20 to 0.86) | 0.42 | 1.07 (1.03 to 1.11) | 0.40 |
| 30–59 | 971/20,427 | 4115/102,392 | 13.7 (12.7 to 14.7) | 12.7 (12.3 to 13.1) | 0.98 (−0.09 to 2.05) | 1.09 (1.01 to 1.18) | ||
| <30 | 69/1168 | 274/5946 | 23.1 (17.6 to 30.9) | 18.8 (16.7 to 21.3) | 4.25 (−2.58 to 11.07) | 1.22 (0.90 to 1.64) | ||
| Proteinuria | ||||||||
| Overall | 1776/152,101 | 7495/795,799 | 3.2 (3.1 to 3.4) | 2.8 (2.7 to 2.8) | 0.47 (0.28 to 0.66) | 1.17 (1.10 to 1.25) | ||
| eGFR (ml/min per 1.73 m2) | ||||||||
| ≥60 | 1155/130,506 | 4971/687,461 | 2.4 (2.3 to 2.6) | 2.1 (2.0 to 2.2) | 0.33 (0.15 to 0.52) | 0.16 | 1.16 (1.07 to 1.25) | 0.74 |
| 30–59 | 552/20,427 | 2225/102,392 | 7.8 (7.1 to 8.6) | 6.7 (6.4 to 7.0) | 1.12 (0.32 to 1.93) | 1.18 (1.06 to 1.31) | ||
| <30 | 69/1168 | 299/5946 | 22.6 (17.1 to 30.6) | 20.5 (18.3 to 23.1) | 2.10 (−4.83 to 9.03) | 1.10 (0.81 to 1.50) | ||
| Urinary tract infection (negative control outcome) | ||||||||
| Overall | 11,829/152,101 | 55,213/795,799 | 21.9 (21.4 to 22.4) | 21.5 (21.3 to 21.7) | 0.42 (−0.08 to 0.93) | 1.02 (1.00 to 1.04) | ||
| eGFR (ml/min per 1.73 m2) | ||||||||
| ≥60 | 8962/130,506 | 41,667/687,461 | 19.0 (18.6 to 19.5) | 18.5 (18.3 to 18.7) | 0.50 (−0.001 to 1.0) | 0.32 | 1.03 (1.00 to 1.05) | 0.31 |
| 30–59 | 2676/20,427 | 12,579/102,392 | 39.9 (38.2 to 41.8) | 40.8 (40.1 to 41.5) | −0.86 (−2.8 to 1.1) | 0.99 (0.94 to 1.03) | ||
| <30 | 191/1168 | 967/5946 | 68.2 (57.7 to 81.0) | 72.0 (67.4 to 76.9) | −3.8 (−16.2 to 8.7) | 0.94 (0.78 to 1.12) | ||
IPTW-HRs were from stratified Cox proportional hazards regression models by cohort. IPTW, inverse-probability of treatment weight; IR, incidence rate; PYs, person-years; IRD, incidence rate difference.
a
P for heterogeneity in IRD across eGFR subgroups was estimated using fixed effects meta-analysis and P for heterogeneity in HR was estimated using stratified Cox models with interaction term between rosuvastatin use and eGFR category.